Longevity is No Longer Just Philosophy: The "Body of the Future" Sold by Wearables and Biotech

Longevity is No Longer Just Philosophy: The "Body of the Future" Sold by Wearables and Biotech

The Place Where People Who "Do Not Accept Death" Gather: Why the Longevity Movement is Becoming a Huge Business

Under the bright sunshine of Berkeley, California, participants sat on folding chairs, taking turns for blood tests. It wasn't a scene of white coats and quiet examination rooms. Instead, there were startup exhibits, conversations with investors, wearable devices, health data, and a sense of excitement over "how much aging can be controlled."

The scene at the longevity conference "Vitalist Bay," reported by the U.S. medical media STAT, symbolizes the current longevity industry. Once, the idea of immortality was often seen as a world of dubious supplements, self-styled diets, and sci-fi fantasies. But now, at its center are biotech companies, clinical researchers, AI drug discovery entrepreneurs, investors, wellness brands, and consumers who measure their body data daily.

The article by STAT captures precisely this turning point. The longevity movement is no longer just an "ideological movement of people who don't want to die." It is becoming a market that includes blood test kits, smart rings, genetic testing, DEXA scans, metabolic improvement drugs, drug discovery companies targeting aging-related diseases, and even concepts of cryopreservation and organ replacement.

Vitalist Bay was held from May 14 to 17, 2026, at the Lighthaven Campus in Berkeley. The organizers position the event as a place to "extend healthy lifespan and solve aging." The themes include biotech, investors, replacement, longevity science, AI×bio, and biostasis. While the words seem very Silicon Valley-esque, the interests of the people gathered there are quite earnest. It's not just about wanting to look young. They perceive aging not as an "inevitable natural phenomenon" but as a "challenge that can be tackled with science, capital, and technology."

The atmosphere is succinctly captured by a question posed by Adam Gries, co-founder of the conference: "Are we just going to give up and die like every generation before us?" This statement is provocative yet well expresses the underlying emotions of the longevity movement: fear, hope, rationalism, rebellious spirit, and market opportunities. These mix together, turning the act of "fighting aging" into a culture.

At the venue, participants attached small blood sampling devices to their upper arms, trying to gain clues about hormones, metabolism, organ function, and biological age. This is a key feature of modern longevity culture. Traditional medicine diagnoses diseases after symptoms appear. In contrast, the longevity business promises to "detect bodily changes through data before symptoms appear." For people who are not yet ill, it quantifies signs of future diseases or decline and intervenes proactively. Here, a vast market is emerging.

The spread of wearable devices and testing businesses is a tailwind for this market. Smart rings like the Oura ring, which measure sleep, heart rate, stress, and recovery on a daily basis, have penetrated health-conscious demographics. Blood tests, genetic tests, gut microbiome tests, and hormone tests have become much more consumer-friendly to sell than before. As data increases, interpretation becomes the next necessity. This is where AI coaches, personalized nutrition, supplements, and preventive medical clinics come into play.

Reactions on social media also reflect this change well. On LinkedIn, there are posts introducing the STAT article as a "brilliant read," and participants of Vitalist Bay have pointed out the current state where wearable data, blood tests, genetic information, and daily life constraints exist separately, expressing expectations for integrated personalized medicine. On the Rapamycin News forum, there are voices evaluating the event as "the best longevity event ever" and reactions like "worth attending for researchers, investors, and serious biohackers." One participant wrote that they initially didn't plan to attend but decided to due to a discount code and FOMO. Here, there is a unique energy that mixes a scientific conference, community event, investment opportunity, and lifestyle consumption.

On the other hand, reactions on social media are not entirely laudatory. There are persistent doubts about the longevity industry, such as "Isn't it a health anxiety business for the wealthy?" "Are expensive procedures being sold without sufficient evidence?" and "Is it really extending lifespan, or just improving health indicators?" Particularly, the numbers shown by blood tests and wearables can help with behavior change, but they do not guarantee longevity in themselves. There is a significant gap between measuring numbers and controlling aging.

Nevertheless, the reasons for the growth of the longevity industry are clear. First, the aging population is advancing, and the burden of chronic diseases is increasing. Second, since the pandemic, people have become more sensitive to themes like their own immunity, inflammation, sleep, weight, and metabolism. Third, the culture of the tech industry has flowed into the medical field. In Silicon Valley, it is often thought that any problem can be optimized, and anything that can be datafied can be improved. Aging is no exception.

According to market research firms, the biohacking market has already reached a scale of tens of billions of dollars and is expected to grow significantly in the future. While there is a range in estimates, there is consensus that the market, including wearables, genetic testing, smart devices, supplements, and personalized healthcare, is rapidly expanding. In other words, longevity is not just a theme of medical research but is at the intersection of consumer technology, wellness, insurance, pharmaceuticals, and investment.

It is noteworthy that what is being sold here is not just "rejuvenation." Rather, the central concept is "healthy lifespan." It's not just about living longer but shortening the period of suffering from illness and decline and extending the active years. This is an important goal both medically and socially. In an aging society, if dementia, cardiovascular diseases, diabetes, muscle weakness, and osteoporosis can be delayed, it will have a significant impact not only on individual quality of life but also on medical costs and caregiving burdens.

That's why there is serious science in longevity research. Research targeting mechanisms related to aging, such as metformin, rapamycin, GLP-1 receptor agonists, senolytic drugs, mTOR pathways, inflammation control, metabolic improvement, and muscle mass maintenance, is actually progressing. Companies like BioAge Labs, which target metabolic diseases and cardiovascular risks based on aging biology, are also emerging. While directly "treating" aging is still difficult both institutionally and scientifically, it is getting closer to the medical front by delaying diseases associated with aging.

However, there is a significant gap in this field. The emergence of promising findings in the lab, extending lifespan in mice, improving biomarkers in humans, and actually extending healthy lifespan or lifespan are all separate stages. Especially consumer-oriented longevity services tend to blur these stage differences. "Measuring indicators related to aging" is often spoken of as if it means "controlling aging." Here lies the danger of excessive marketing.

Moreover, the longevity business also faces the issue of inequality. Expensive tests, membership clinics, cutting-edge supplements, personalized programs, full-body scans, and dedicated coaches are often aimed at those with time and money to spare. If technology that truly extends healthy lifespan is developed, who will it reach? Will it be a society where only the wealthy can delay aging while the low-income continue to access healthcare after becoming ill as usual? This question becomes heavier as the longevity industry grows.

The enthusiasm seen on social media also reflects this stratification. Events like Vitalist Bay are intellectually stimulating places and communities where future-oriented people gather. But at the same time, tickets, tests, supplements, investments, and networking are incorporated into them. Participants discuss future medicine while also participating in the current market. Resistance to aging is an ideology, a science, and a consumption.

So, how should we evaluate this movement? It's easy to simply dismiss it as "suspicious," but that would misinterpret reality. It is widely known that factors such as sleep, exercise, nutrition, muscle strength, metabolism, blood pressure, inflammation, loneliness, and mental health are significantly related to healthy lifespan. If technology helps people change their behavior and leads to early detection of diseases, its value is significant. The shift in medicine from treatment-centered to prevention-centered is also socially rational.

However, for the longevity business to truly hold value, it must distinguish between "what can be measured" and "what is meaningful." Just because a sleep score has increased doesn't mean lifespan has been extended. Just because the numbers on a biological age test have decreased doesn't necessarily mean future disease risk has significantly reduced. Taking expensive tests doesn't mean one has become healthy. Data is a tool, not salvation.

The intrigue of the longevity movement lies in how it markets fundamental human questions in a very modern way. Why do people fear death? How long do they want to live? What is health? Is the body a project to be managed by oneself? Or is accepting aging also part of being human? Participants at Vitalist Bay are trying to answer these questions not with philosophy but with products, clinical trials, investment, and community.

This movement is likely to expand further. Wearables will become smaller, blood tests easier, AI will interpret individual health data, and pharmaceutical companies will intensify interventions in aging-related diseases. Longevity clinics may expand from services for the wealthy to packages for the middle class. Insurance companies and employers might introduce preventive programs utilizing health data.

However, whether that future will be bright depends on scientific evidence, regulation, ethics, and fairness of access. Will the longevity industry become a "market that stirs anxiety and sells tests and supplements," or a "medical innovation that delays aging-related diseases and extends healthy lifespan"? That crossroads is already before us.

The Berkeley venue depicted in the STAT article housed both dreams and commerce. Participants offered their blood, received data, and discussed the future of their bodies. There was absurdity, seriousness, hope, and danger. The new industry surrounding aging is questioning us. Before we can completely conquer death, how far should we commodify the desire to "live longer and better"?


Source URL

Related Articles